{"abstract":"This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in U.S. Provisional Patent Application No. 60/178,689, filed January 28, 2000 [HHS Ref. No. E-088-2000/0-US-01], now expired; PCT Patent Application No. PCT/US01/02686 [HHS Ref. No. E-088-2000/0-PCT-02] filed January 26, 2001, which published as WO/2001/54718 on August 2, 2001, now expired; U.S. Patent No. 7,431,931 [HHS Ref. No. E-088-2000/0-US-06]; Australian Patent No. 784344 [HHS Ref. No. E-088-2000/0-AU-04]; German Patent No. 60141681.308 [HHS Ref. No. E-088-2000/0-DE-08]; French Patent No. 1251869 [HHS Ref. No. E-088-2000/0-FR-09]; United Kingdom Patent No. 1251869 [HHS Ref. No. E-088-2000/0-GB-10]; and Canadian Patent Application No. 2398428 [HHS Ref. No. E-088-2000/0-CA-05], entitled \"Compositions and Method for Preventing Reactogenicity Associated with Administration of Immunogenic Live Rotavirus Compositions,\" and all continuing applications to International Medica Foundation, having a place of business in Rochester, Minnesota. The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive license territory may be \"worldwide\", and the field of use may be limited to \"rhesus-based rotavirus therapeutic and/or prophylactic vaccines.\"","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2011/09/29/2011-25098.html","cfr_references":[],"citation":"76 FR 60510","comment_url":null,"comments_close_on":"2011-10-31","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before October 31, 2011 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2011-25098","effective_on":null,"end_page":60510,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2011/09/29/2011-25098.xml","html_url":"https://www.federalregister.gov/documents/2011/09/29/2011-25098/prospective-grant-of-exclusive-license-compositions-and-method-for-preventing-reactogenicity","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2011-25098?publication_date=2011-09-29","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2011-09-29/2011-25098/mods.xml","not_received_for_publication":null,"page_length":1,"page_views":{"count":42,"last_updated":"2026-07-28 12:15:07 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2011-09-29/pdf/2011-25098.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":null,"publication_date":"2011-09-29","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2011/09/29/2011-25098.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"supporting_documents":[],"comments_url":"https://www.regulations.gov/docketBrowser?rpp=50&so=DESC&sb=postedDate&po=0&dct=PS&D=NIH_FRDOC_0001","supporting_documents_count":0,"docket_id":"NIH_FRDOC_0001","regulation_id_number":null,"title":"Recently Posted NIH Rules and Notices.","checked_regulationsdotgov_at":"2011-10-19T08:09:59Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":60510,"subtype":null,"title":"Prospective Grant of Exclusive License: Compositions and Method for Preventing Reactogenicity Associated with Administration of Immunogenic Live Rotavirus Compositions","toc_doc":"Compositions and Method for Preventing Reactogenicity Associated with Administration of Immunogenic Live Rotavirus Compositions","toc_subject":"Prospective Grants of Exclusive Licenses:","topics":[],"type":"Notice","volume":76}